A quality improvement project to address the challenges surrounding zoledronic acid use in children

[1]  Qin Fan,et al.  The efficacy and safety of bisphosphonates for osteoporosis in women older than 65 years: a meta-analysis. , 2020, Current pharmaceutical design.

[2]  L. Hornung,et al.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy , 2019, Osteoporosis International.

[3]  C. Gordon,et al.  Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. , 2019, Bone.

[4]  A. Siafarikas,et al.  Consensus guidelines on the use of bisphosphonate therapy in children and adolescents , 2018, Journal of paediatrics and child health.

[5]  J. Mahan,et al.  Zoledronic acid in pediatric metabolic bone disorders. , 2017, Translational pediatrics.

[6]  M. Ong,et al.  Improving Bisphosphonate Infusion Monitoring at Haematology Medical Day Unit , 2017, BMJ quality improvement reports.

[7]  P. Tebben,et al.  Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child , 2016, Osteoporosis International.

[8]  F. Glorieux,et al.  Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Greg Ogrinc,et al.  Squire 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. , 2015, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[10]  F. Davidoff,et al.  SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): Revised Publication Guidelines From a Detailed Consensus Process. , 2015, Journal of continuing education in nursing.

[11]  P. Kaplan,et al.  Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. , 2015, The Journal of clinical endocrinology and metabolism.

[12]  G. Eghbali-Fatourechi.  Bisphosphonate therapy in pediatric patients , 2014, Journal of Diabetes & Metabolic Disorders.

[13]  A. McCormick,et al.  The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy , 2012, Osteoporosis International.

[14]  R. McCall,et al.  Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[15]  C. Cowell,et al.  Acute phase response and mineral status following low dose intravenous zoledronic acid in children. , 2007, Bone.